Aggredyne Raises $3M

Houston-based Aggredyne, a developer of biomedical diagnostics products for measuring platelet function, said today that it has raised $3M in a Series A funding round. The firm, which is headed by Edward R. Teitel, did not disclose the source of the new funding. The firm said its technology was originally developed at the Utah Artificial Heart Institute and originally licensed from Brigham Young University to Thrombodyne, and that it now has exclusive rights to the patents and technology. The firm was represented by Paul Pryzant of Burleson LLP in Houston. More information »